AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection

Published: 16 November 2023

  • Views:

    Views Icon 1976
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family. 


These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

About the episode

AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.


The ORBITA-2 trial enrolled  439 patients eligible for percutaneous coronary intervention (PCI), who met specific inclusion criteria. These criteria included the presence of angina or angina-equivalent symptoms, the presence of anatomical evidence showing severe coronary stenosis in at least one vessel as determined through invasive diagnostic angiography or computerized tomography coronary angiography (CTCA), as well as the manifestation of evidence indicating myocardial ischemia. The primary outcome is an angina symptom score measured daily. 


Findings suggest that in stable angina, PCI without anti-anginal therapy improved angina symptom score, reduced angina frequency, increased exercise capacity and improved quality of life. The effect of PCI was immediate and sustained over 12 weeks, however, this effect size was smaller than in comparable unblinded trials. 

Recorded on-site at AHA 2023, Philadelphia.


Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

Faculty Biographies

Rasha Al-Lamee

Rasha Al-Lamee

Interventional Cardiology Consultant

Dr Rasha Al-Lamee is an interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, UK.  

Dr Al-Lamee studied at the University of Oxford and University College London. She completed her training in clinical cardiology on the north-west London cardiology rotation in 2013, and completed her PhD at Imperial College London in 2018.

Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is lead author of the primary publication in The Lancet. Dr Al-Lamee has more than 50 peer-reviewed publications and has presented at international cardiology conferences worldwide.  

View full profile
Nazli Okumus

Nazli Okumus

Dr. Nazli Okumus is currently in her third year as a Cardiology Fellow at Allegheny Health Network (AHN) in Pittsburgh, PA, where she is dedicated to advancing her training in interventional cardiology. She successfully completed her residency at Case Western MetroHealth in Cleveland, OH. Her commitments extend to serving as a member of the SCAI Political Action Committee, contributing to the ACC FIT Editorial Fellowship program Advocacy section, and acting as the CardioNerds Ambassador, representing her fellowship program while participating in the CardioNerds IC and CCC committees. In addition, she is actively engaged in digital education and mentorship, with a particular emphasis on empowering women in medicine. Her research and clinical interests encompass cardiogenic shock, valvular heart disease, and complex coronary interventions. Dr. Okumus is fervently committed to patient advocacy and addressing health disparities.

View full profile

Christopher Rajkumar

View full profile


You must be to comment. If you are not registered, you can register here.